2021
Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
Matye D, Wang H, Luo W, Sharp R, Chen C, Gu L, Jones K, Ding W, Friedman J, Li T. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. Cellular And Molecular Gastroenterology And Hepatology 2021, 12: 1001-1019. PMID: 33965587, PMCID: PMC8346663, DOI: 10.1016/j.jcmgh.2021.04.013.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDependovirusDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression ProfilingGene Expression RegulationGenetic TherapyGenetic VectorsMaleMethylaminesMiceNon-alcoholic Fatty Liver DiseaseThiazepinesTreatment OutcomeConceptsNonalcoholic steatohepatitisBile acid synthesisTherapeutic efficacyFGF19 analogueASBT inhibitorTreatment-associated adverse eventsFecal bile acid excretionASBT inhibitionDiet-induced nonalcoholic steatohepatitisHepatic bile acid synthesisWeight lossBile acid excretionGrowth factor 15Experimental nonalcoholic steatohepatitisDiet-fed miceFurther clinical studiesNew treatment strategiesIntestinal lipid absorptionAdverse eventsAdipose inflammationMetabolic improvementTreatment attenuatesLipid malabsorptionClinical findingsTreatment strategies
2018
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
Abu-Sbeih H, Ali F, Alsaadi D, Jennings J, Luo W, Gong Z, Richards D, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. Journal For ImmunoTherapy Of Cancer 2018, 6: 142. PMID: 30518410, PMCID: PMC6280383, DOI: 10.1186/s40425-018-0461-4.Peer-Reviewed Original ResearchConceptsMean durationImmune checkpoint inhibitor-induced colitisCheckpoint inhibitor-induced colitisImmune checkpoint inhibitor treatmentAbnormal endoscopic findingsActive histologic inflammationCheckpoint inhibitor treatmentClinical success rateRetrospective case seriesGood safety profileFeatures of chronicityMulti-center studyEndoscopic remissionHistologic inflammationHistologic remissionICI therapyNonulcerative inflammationSteroid therapyVedolizumab infusionsVedolizumab therapyClinical remissionMicroscopic colitisMucosal ulcerationSystemic immunosuppressionAdvanced malignancies
2014
Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature.
Luo W, Lindley S, Lindley P, Krempl G, Seethala R, Fung K. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. International Journal Of Clinical And Experimental Pathology 2014, 7: 9008-22. PMID: 25674280, PMCID: PMC4313953.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorBiopsyBreast NeoplasmsCarcinomaCranial IrradiationFemaleHumansImmunohistochemistryLymphatic MetastasisMagnetic Resonance ImagingNeoplasm GradingOncogene Proteins, FusionPalatal NeoplasmsPalate, HardRadiotherapy, AdjuvantRecombination, GeneticSalivary Gland NeoplasmsTomography, X-Ray ComputedTreatment OutcomeConceptsHigh-grade histologyMinor salivary glandsETV6-NTRK3 translocationSalivary gland tumorsParotid glandSalivary glandsGrade histologySecretory carcinomaHard palateOriginal tumorGland tumorsCervical lymph node metastasisMammary analogue secretory carcinomaPrimary salivary gland tumorsLow histologic gradeLymph node metastasisLow-grade malignancyAcinic cell carcinomaYears of ageHigh-grade transformationYear old adultsReview of literatureOverall prognosisBenign courseNode metastasis